JP2007510667A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510667A5
JP2007510667A5 JP2006538522A JP2006538522A JP2007510667A5 JP 2007510667 A5 JP2007510667 A5 JP 2007510667A5 JP 2006538522 A JP2006538522 A JP 2006538522A JP 2006538522 A JP2006538522 A JP 2006538522A JP 2007510667 A5 JP2007510667 A5 JP 2007510667A5
Authority
JP
Japan
Prior art keywords
inhibitor
solvate
iii
salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037027 external-priority patent/WO2005046678A1/en
Publication of JP2007510667A publication Critical patent/JP2007510667A/ja
Publication of JP2007510667A5 publication Critical patent/JP2007510667A5/ja
Pending legal-status Critical Current

Links

JP2006538522A 2003-11-07 2004-11-05 癌の治療法 Pending JP2007510667A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51821203P 2003-11-07 2003-11-07
PCT/US2004/037027 WO2005046678A1 (en) 2003-11-07 2004-11-05 Cancer treatment method

Publications (2)

Publication Number Publication Date
JP2007510667A JP2007510667A (ja) 2007-04-26
JP2007510667A5 true JP2007510667A5 (enExample) 2007-12-27

Family

ID=34590233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538522A Pending JP2007510667A (ja) 2003-11-07 2004-11-05 癌の治療法

Country Status (4)

Country Link
US (1) US20070161665A1 (enExample)
EP (1) EP1682123A1 (enExample)
JP (1) JP2007510667A (enExample)
WO (1) WO2005046678A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
MX2007004551A (es) 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
EP2024372B1 (en) * 2006-04-26 2010-06-23 F.Hoffmann-La Roche Ag Thieno[3,2-d]pyrimidine derivative useful as pi3k inhibitor
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
CN101594870A (zh) * 2006-08-22 2009-12-02 康塞特医药品有限公司 4-氨基喹唑啉衍生物及其使用方法
JPWO2008032876A1 (ja) * 2006-09-15 2010-01-28 学校法人東海大学 Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
WO2008063853A2 (en) * 2006-11-21 2008-05-29 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
CN102027371A (zh) * 2008-05-16 2011-04-20 塞尔卓姆股份公司 Parp相互作用分子的鉴定方法和parp蛋白的纯化方法
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
AU2010266725A1 (en) 2009-07-02 2012-02-23 Newgen Therapeutics, Inc. Phosphorus containing quinazoline compounds and methods of use
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
CN104109152A (zh) * 2013-04-19 2014-10-22 上海医药工业研究院 一种制备拉帕替尼的方法
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2020078865A1 (en) 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Use of akt inhibitors in ophthalmology
AU2024210779A1 (en) * 2023-01-20 2025-07-31 Rinascera Therapeutics, Inc. Compositions and formulations for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP2001247477A (ja) * 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält

Similar Documents

Publication Publication Date Title
JP2007510667A5 (enExample)
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
PT1506781E (pt) Composicao para tratamento vaginal
JP2009502793A5 (enExample)
JP2009502743A5 (enExample)
EE05394B1 (et) Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
LT2803366T (lt) Kompozicijos, skirtos su oksalatu susijusių ligų gydymui arba prevencijai
JP2007537301A5 (enExample)
ZA200610640B (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
PL1701944T3 (pl) (2-Amino-podstawione)-4-arylopirymidyny i związki pokrewne, użyteczne do leczenia chorób zapalnych
JP2008513510A5 (enExample)
JP2006514116A5 (enExample)
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
FR2864552B1 (fr) Traitement de surface par hydroxysulfate
JP2004502684A5 (enExample)
WO2008028963A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal
JP2008524329A5 (enExample)
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
JP2005509503A5 (enExample)
JP2008517059A5 (enExample)
SI1545710T1 (sl) Uporaba N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamida v zdravljenju raka
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer
DK1803456T5 (da) Farmaceutiske sammensætninger omfattende L-733060 til anvendelse ved behandling af cancertumorer
EP1640387A4 (en) TREATMENT AGENT FOR MAUERWERK
EP1840948A4 (en) FINE TREATMENT AGENT AND THIS USE FINE TREATMENT METHOD